M T E Puts1, J Monette2, V Girre3, C Wolfson4, M Monette5, G Batist6, H Bergman2. 1. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto; Solidage Research Group on Frailty and Aging, McGill University/Université de Montreal, Jewish General Hospital, Montreal. Electronic address: martine.puts@utoronto.ca. 2. Solidage Research Group on Frailty and Aging, McGill University/Université de Montreal, Jewish General Hospital, Montreal; Division of Geriatric Medicine, Jewish General Hospital, McGill University, Montreal; Department of Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Canada. 3. Solidage Research Group on Frailty and Aging, McGill University/Université de Montreal, Jewish General Hospital, Montreal; Department of Medical Oncology, Institut Curie, Paris, France. 4. Division of Clinical Epidemiology, McGill University Health Centre, McGill University, Montreal, Canada. 5. Solidage Research Group on Frailty and Aging, McGill University/Université de Montreal, Jewish General Hospital, Montreal. 6. Department of Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Canada.
Abstract
BACKGROUND: The aim of this prospective study was to report the quality of life (QoL) of older cancer patients during the first year after diagnosis and factors influencing QoL. PATIENTS AND METHODS: Newly diagnosed patients aged ≥65 years were recruited for a pilot prospective cohort study at the Jewish General Hospital, Montreal, Canada. Participants were interviewed at baseline, and at 1.5, 3, 4.5, 6, and 12 months. QoL was assessed at each interview using the European Organization for the Research and Treatment of Cancer Quality of Life Core Questionnaire with 30 items. Logistic regression was conducted to determine which sociodemographic, health, and functional status characteristics were associated with decline in global health status/QoL between baseline and 12-month follow-up. RESULTS: There were 112 participants at baseline (response rate 72%), median age of 74.1, and 70% were women. Between baseline and 12-month follow-up (n=78), 18 participants (23.1%) declined ≥10 points in global health status/QoL, while 34 participants (43.6%) remained stable and 23 participants (33.3%) improved ≥10 points. None of the sociodemographic, health, and functional status variables were associated with decline in logistic regression analyses. CONCLUSION: Almost 25% of older adults experienced clinically relevant decline in their QoL. Further research is needed on which factors influence decline in QoL in older adults.
BACKGROUND: The aim of this prospective study was to report the quality of life (QoL) of older cancerpatients during the first year after diagnosis and factors influencing QoL. PATIENTS AND METHODS: Newly diagnosed patients aged ≥65 years were recruited for a pilot prospective cohort study at the Jewish General Hospital, Montreal, Canada. Participants were interviewed at baseline, and at 1.5, 3, 4.5, 6, and 12 months. QoL was assessed at each interview using the European Organization for the Research and Treatment of Cancer Quality of Life Core Questionnaire with 30 items. Logistic regression was conducted to determine which sociodemographic, health, and functional status characteristics were associated with decline in global health status/QoL between baseline and 12-month follow-up. RESULTS: There were 112 participants at baseline (response rate 72%), median age of 74.1, and 70% were women. Between baseline and 12-month follow-up (n=78), 18 participants (23.1%) declined ≥10 points in global health status/QoL, while 34 participants (43.6%) remained stable and 23 participants (33.3%) improved ≥10 points. None of the sociodemographic, health, and functional status variables were associated with decline in logistic regression analyses. CONCLUSION: Almost 25% of older adults experienced clinically relevant decline in their QoL. Further research is needed on which factors influence decline in QoL in older adults.
Authors: Vic Velanovich; Molly Gabel; Eleanor M Walker; Thomas J Doyle; Robert M O'Bryan; Wanda Szymanski; John J Ferrara; Frank R Lewis Journal: J Am Coll Surg Date: 2002-01 Impact factor: 6.113
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays Journal: Cancer Date: 2014-11-04 Impact factor: 6.860
Authors: Megan M Chock; Maria I Lapid; Pamela J Atherton; Simon Kung; Jeff A Sloan; Jarrett W Richardson; Matthew M Clark; Teresa A Rummans Journal: Int Psychogeriatr Date: 2013-09-04 Impact factor: 3.878
Authors: M E Giuliani; R A Milne; M Puts; L R Sampson; J Y Y Kwan; L W Le; S M H Alibhai; D Howell; N Abdelmutti; G Liu; J Papadakos; P Catton; J Jones Journal: Curr Oncol Date: 2016-08-12 Impact factor: 3.677
Authors: Mackenzi Pergolotti; Allison M Deal; Grant R Williams; Ashley L Bryant; Jeannette T Bensen; Hyman B Muss; Bryce B Reeve Journal: J Geriatr Oncol Date: 2017-03-09 Impact factor: 3.599
Authors: M M Muñoz-Sánchez; C Calderon; P Jimenez-Fonseca; M C Soriano-Rodríguez; C Jara; T García-García; C Beato; J Rogado; B Castelo; R Hernández; M Mangas-Izquierdo; A Carmona-Bayonas Journal: Clin Transl Oncol Date: 2018-06-04 Impact factor: 3.405
Authors: Laura Deckx; Marjan van den Akker; Liesbeth Daniels; Eric T De Jonge; Paul Bulens; Vivianne C G Tjan-Heijnen; Doris L van Abbema; Frank Buntinx Journal: BMC Fam Pract Date: 2015-03-03 Impact factor: 2.497